Jeroen Goos

Jeroen Goos

Research Specialist
Visiting address: BioClinicum J5:20, Akademiska Stråket 1, Universitetssjukhuset Solna, 17176 Stockholm
Postal address: K8 Klinisk neurovetenskap, K8 Neuro Holmin Goos, 171 77 Stockholm
Part of:

Research

  • The focus of my research group lies with the development of new tools for the
    molecular imaging and treatment of patients with cancer. We use synthetic
    molecules, but also biological compounds, that are labelled with radioactive
    isotopes to specifically target the sites in the body where tumours are
    located. Some of these isotopes can be detected using diagnostic imaging
    devices (e.g. PET), whereas other isotopes are more suited for the delivery
    of therapeutic doses of radioactivity that kill the tumour cells.
    Our first research line aims at developing minimally invasive, nuclear
    treatment strategies for patients that suffer from brain cancer. We are
    using natural peptides and bispecific antibodies that are capable to
    cross the blood-brain barrier (BBB) and then specifically bind to tumour
    tissue.
    In our second research line, we are developing new (radio)chemistry to
    improve current pretargeting strategies. The pretargeting strategy
    attempts to decrease radioactive doses to healthy tissues by injecting the
    targeting vector (e.g. an antibody) and radioactive ligand separately, which
    then ligate within the target tissue. By optimising the chemical and
    physiological properties of both, the radioactive doses to healthy
    tissues can significantly be reduced.
    In our third research line, we use imaging isotopes to track immune cells in
    the human body during immune cell therapy.

Articles

All other publications

Grants

  • Swedish Research Council
    1 January 2022 - 31 December 2025
    One in three children with brain cancer dies before reaching adulthood. Standard therapy involves opening of the skull for physical removal of the tumour. This highly invasive treatment comes with significant risks. Moreover, an incomplete resection will lead to relapse and decreased survival. My aim is to develop an innovative, minimally invasive therapy approach that effectively and selectively delivers radiotherapeutic agents to brain tumours, with minimal side effects.My team (one PhD student and one postdoc) will design a new class of bispecific monoclonal antibodies (month 1-24) and use a peptide from scorpion venom (month 1-18) for the delivery of therapeutic radionuclides across the blood-brain barrier (BBB). A pretargeting strategy will be employed to reduce radioactive doses to healthy tissues (month 1-48).This proposal uniquely integrates recent advances in radiology, oncology, chemistry and molecular biology into innovative research designs and novel treatment strategies. The proposed strategy will limit side effects with a substantial chance of significant tumour reduction or complete tumour elimination. The newly designed methodologies and agents could lead to breakthroughs in key applications of fundamental, preclinical and clinical interest and change the way we approach illnesses of the brain. The feasibility of the suggested approach is supported by preliminary data. This proposal will open up new fields of research in the basic and (pre)clinical setting.

Employments

  • Research Specialist, Department of Clinical Neuroscience, Karolinska Institutet, 2025-
  • Assistant Professor, Department of Clinical Neuroscience, Karolinska Institutet, 2019-2025

News from KI

Events from KI